anti-CD64 antibody-drug conjugate (Tokyo Medical and Dental University/Kyowa Hakko Kirin)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD64 antibody-drug conjugate (Tokyo Medical and Dental University/Kyowa Hakko Kirin)
Drug Alias Nameanti-CD64-dPBD ADC (Tokyo Medical and Dental University/Kyowa Hakko Kirin)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionHigh affinity immunoglobulin gamma Fc receptor I antagonists
TargetsHigh affinity immunoglobulin gamma Fc receptor I
Therapy Area/IndicationsSolid tumoursInflammationAutoimmune Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTokyo Medical And Dental University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Kirin Co LtdTokyo Medical And Dental University
Active IndicationsN/A
Inactive IndicationsSolid tumoursInflammationAutoimmune Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A